Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide added to salvage radiotherapy and LHRH agonist in high-risk hormone-sensitive recurrent prostate cancer
2023-505852-23-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate cancer (PCa) and prostate-specific antigen persistence (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: PSMA-PET metastatic progression-free survival. Planned start Feb 2024; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)prostate-specific antigen persistence
Beyond the preview
Go deeper on 2023-505852-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505852-23-00.